Avidity Biosciences joined PPMD for a community webinar on November 19, 2025, during which the company shared topline and functional data from their EXPLORE44-OLE® clinical trial. Avidity’s investigational therapy, delpacibart zotadirsen (abbreviated as del-zota), is in development for individuals with Duchenne muscular dystrophy who are amenable to exon 44 skipping.
In addition to presenting insights from the EXPLORE44-OLE study, the company answered questions from the community and addressed recent news about Avidity’s Managed Access Program (MAP) for del-zota for eligible individuals living with Duchenne who are amenable to exon 44 skipping in the United States.
In October 2025, Avidity shared the completion of a positive pre-Biologics License Application (BLA) meeting with the FDA regarding its upcoming BLA submission of del-zota, and indicated that the submission is planned for 2026 for accelerated approval.
If you missed the live webinar with Avidity or would like to revisit any of the content shared, you can watch the recording below.
Watch the Recording
The post Watch the Recording: Avidity Biosciences – EXPLORE44-OLE® Topline and Functional Data Presentation appeared first on Parent Project Muscular Dystrophy.